

Filippo de Braud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7230534/publications.pdf>

Version: 2024-02-01

458
papers

28,596
citations

9254

74
h-index

7152

153
g-index

464
all docs

464
docs citations

464
times ranked

33157
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	13.9	1,572
2	Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 663-671.	0.8	1,524
3	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	6.3	1,175
4	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 883-895.	5.1	1,091
5	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. <i>Annals of Oncology</i> , 2011, 22, 1535-1546.	0.6	696
6	Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1465-1471.	0.8	669
7	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1590-1598.	5.1	594
8	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , 2013, 45, 1470-1473.	9.4	564
9	Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 813-824.	13.9	505
10	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , 2017, 552, 116-120.	13.7	480
11	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2836-2844.	0.8	459
12	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, 587-594.	1.3	425
13	Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. <i>Annals of Oncology</i> , 2002, 13, 73-80.	0.6	421
14	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 127-164.	2.0	347
15	Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. <i>Cancer Discovery</i> , 2016, 6, 492-500.	7.7	319
16	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 261-270.	5.1	303
17	Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 1234-1243.	5.1	297
18	Colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 106-133.	2.0	285

#	ARTICLE	IF	CITATIONS
19	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019, 120, 165-171.	2.9	279
20	Caring for patients with cancer in the COVID-19 era. <i>Nature Medicine</i> , 2020, 26, 665-671.	15.2	269
21	Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production. <i>Cancer Research</i> , 2005, 65, 2964-2971.	0.4	263
22	Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression. <i>Journal of Clinical Oncology</i> , 2011, 29, 2372-2377.	0.8	261
23	Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research. <i>Journal of Clinical Oncology</i> , 2007, 25, 3217-3223.	0.8	247
24	Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients. <i>Journal of Clinical Oncology</i> , 2007, 26, 102-109.	0.8	243
25	Totally implantable central venous access ports for long-term chemotherapy A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. <i>Annals of Oncology</i> , 1998, 9, 767-773.	0.6	241
26	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , 2019, 14, 237-244.	0.5	241
27	Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3733-3740.	0.8	217
28	Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5407-5415.	0.8	214
29	Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. <i>Annals of Oncology</i> , 1998, 9, 105-108.	0.6	205
30	Fasting-mimicking diet and hormone therapy induce breast cancer regression. <i>Nature</i> , 2020, 583, 620-624.	13.7	198
31	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020, 21, 497-507.	5.1	196
32	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 5505-5516.	3.9	193
33	Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. <i>Annals of Oncology</i> , 2009, 20, 935-940.	0.6	192
34	Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 426-434.	2.2	186
35	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.	0.8	185
36	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	183

#	ARTICLE	IF	CITATIONS
37	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>Journal of Thoracic Oncology</i> , 2020, 15, 426-435.	0.5	181
38	Breast carcinoma in elderly women. <i>Cancer</i> , 2004, 101, 1302-1310.	2.0	176
39	Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 348-357.	3.3	172
40	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. <i>Oncotarget</i> , 2014, 5, 2839-2852.	0.8	171
41	Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails. <i>Journal of Clinical Oncology</i> , 2005, 23, 1867-1874.	0.8	163
42	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. <i>Annals of Oncology</i> , 2014, 25, 2244-2251.	0.6	153
43	Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 511-521.	1.2	153
44	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. <i>American Journal of Transplantation</i> , 2016, 16, 2892-2902.	2.6	151
45	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019, 4, e000457.	2.0	151
46	The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2010, 46, 2926-2935.	1.3	149
47	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2414-2422.	3.2	148
48	A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. <i>Cancer</i> , 2001, 92, 1204-1212.	2.0	141
49	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1319-1327.	0.5	138
50	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015, 26, 2092-2097.	0.6	137
51	Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. <i>Cancer Discovery</i> , 2016, 6, 1315-1333.	7.7	137
52	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 53-66.	2.0	137
53	A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 7732-7742.	3.2	134
54	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 810-816.	5.1	130

#	ARTICLE	IF	CITATIONS
55	Safety and antitumor activity of the anti-“PD-1 antibody pembrolizumab in patients with advanced, PD-L1-“positive papillary or follicular thyroid cancer. <i>BMC Cancer</i> , 2019, 19, 196.	1.1	126
56	Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. <i>Endocrine-Related Cancer</i> , 2007, 14, 473-482.	1.6	124
57	Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. <i>Cancer Discovery</i> , 2022, 12, 90-107.	7.7	124
58	Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. <i>European Journal of Cancer</i> , 2004, 40, 1872-1877.	1.3	120
59	Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1895-1901.	0.5	117
60	Phase II Study of Asparagine-Glycine-Arginine-“Human Tumor Necrosis Factor β , a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2604-2611.	0.8	111
61	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 1994-1999.	0.6	105
62	Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: Experience from 178 cases using a single type of device. <i>European Journal of Cancer</i> , 1997, 33, 1190-1194.	1.3	103
63	Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications?. <i>Annals of Thoracic Surgery</i> , 2004, 77, 260-265.	0.7	103
64	HER2 loss in HER2-“positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. <i>International Journal of Cancer</i> , 2016, 139, 2859-2864.	2.3	94
65	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994.	1.9	94
66	Phase I/II study of the tumour-targeting human monoclonal antibody-“cytokine fusion protein L19-TNF in patients with advanced solid tumours. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 447-455.	1.2	92
67	Cancer of the prostate. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 379-396.	2.0	89
68	Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 223-230.	3.3	88
69	Dendritic cell sarcoma: An analytic overview of the literature and presentation of original five cases. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 1-7.	2.0	86
70	Ramucirumab and durvalumab for previously treated, advanced non-“small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). <i>European Journal of Cancer</i> , 2020, 137, 272-284.	1.3	86
71	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i> -Mutated Colorectal Cancer. <i>Cancer Discovery</i> , 2016, 6, 963-971.	7.7	85
72	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. <i>Oncologist</i> , 2014, 19, 966-974.	1.9	84

#	ARTICLE	IF	CITATIONS
73	Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. <i>Oncotarget</i> , 2016, 7, 4428-4441.	0.8	84
74	Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. <i>Cancer Treatment Reviews</i> , 2019, 72, 45-55.	3.4	82
75	Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 148-163.	0.6	81
76	Interferon- γ and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?. <i>Annals of Oncology</i> , 2007, 18, 13-19.	0.6	80
77	Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara [®]) in breast cancer patients. <i>Biopharmaceutics and Drug Disposition</i> , 2001, 22, 191-197.	1.1	79
78	Extended Pneumonectomy With Partial Resection of the Left Atrium, Without Cardiopulmonary Bypass, for Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2005, 79, 234-240.	0.7	77
79	Breast cancer vaccines: a clinical reality or fairy tale?. <i>Annals of Oncology</i> , 2006, 17, 750-762.	0.6	76
80	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	3.2	76
81	A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. <i>European Journal of Cancer</i> , 2013, 49, 290-296.	1.3	74
82	miR-9 and miR-200 Regulate PDGFR β -Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016, 76, 5562-5572.	0.4	74
83	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1253-1263.	0.8	74
84	Gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 54, 209-241.	2.0	73
85	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	1.3	71
86	Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. <i>Annals of Oncology</i> , 2015, 26, 657-668.	0.6	71
87	Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. <i>Cancer</i> , 1995, 75, 1649-1656.	2.0	70
88	Targeting the MET gene for the treatment of non-small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 284-299.	2.0	70
89	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1268.	3.4	70
90	A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. <i>Annals of Oncology</i> , 2011, 22, 1413-1419.	0.6	69

#	ARTICLE	IF	CITATIONS
91	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. <i>Annals of Oncology</i> , 2014, 25, 404-408.	0.6	67
92	Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer. <i>Pharmacological Reviews</i> , 2003, 55, 57-103.	7.1	65
93	Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. <i>British Journal of Cancer</i> , 2011, 104, 1686-1690.	2.9	65
94	Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 3099-3110.	0.8	65
95	Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. <i>Lung Cancer</i> , 2012, 77, 507-514.	0.9	64
96	Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors. <i>Cancer</i> , 2006, 107, 2474-2481.	2.0	63
97	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 156-166.	2.0	61
98	Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF- β 2) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 35-40.	1.1	59
99	Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. <i>Annals of Oncology</i> , 2014, 25, 1597-1603.	0.6	59
100	Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. <i>Annals of Oncology</i> , 2008, 19, 173-177.	0.6	58
101	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016, 11, e0151662.	1.1	56
102	Phospho-TCTP as a therapeutic target of dihydroartemisinin for aggressive breast cancer cells. <i>Oncotarget</i> , 2015, 6, 5275-5291.	0.8	56
103	Malignant melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 47, 35-63.	2.0	55
104	Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2012, 96, 32-40.	1.2	55
105	Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies. <i>PLoS ONE</i> , 2014, 9, e108940.	1.1	55
106	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab \pm Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3926-3935.	3.2	55
107	Pharmacogenetic determinants of anti-cancer drug activity and toxicity. <i>Trends in Pharmacological Sciences</i> , 2001, 22, 420-426.	4.0	54
108	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	0.6	54

#	ARTICLE	IF	CITATIONS
109	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 72-78.	0.9	54
110	Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. <i>European Journal of Cancer</i> , 2009, 45, 1153-1161.	1.3	53
111	Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 1964-1972.	3.2	53
112	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 581-588.	1.1	52
113	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O ⁶ -Methylguanine- ⁸ DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1562-1573.	0.8	52
114	Brief Report: Activity of Imatinib in a Patient with Platelet-Derived-Growth-Factor Receptor Positive Malignant Solitary Fibrous Tumor of the Pleura. <i>Journal of Thoracic Oncology</i> , 2008, 3, 938-941.	0.5	51
115	Î ¹²⁵ Np63 (p40) Distribution Inside Lung Cancer. <i>International Journal of Surgical Pathology</i> , 2013, 21, 229-239.	0.4	51
116	The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. <i>Cell Adhesion and Migration</i> , 2015, 9, 14-21.	1.1	51
117	Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. <i>European Journal of Surgical Oncology</i> , 2017, 43, 380-387.	0.5	51
118	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor Î ² (TGFÎ ²) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. <i>Investigational New Drugs</i> , 2014, 32, 555-560.	1.2	50
119	A review on biomarkers for prediction of treatment outcome in gastric cancer. <i>Anticancer Research</i> , 2013, 33, 1257-66.	0.5	50
120	Oxaliplatin added to 5-fluorouracil-based therapy (5-FU ± FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program. <i>Annals of Oncology</i> , 1999, 10, 1311-1316.	0.6	49
121	Gemcitabine-induced systemic capillary leak syndrome. <i>Annals of Oncology</i> , 2001, 12, 1651-1652.	0.6	49
122	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. <i>Oncologist</i> , 2014, 19, 845-850.	1.9	48
123	Role of cMET in the Development and Progression of Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 18056-18077.	1.8	47
124	Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis. <i>Current Drug Targets</i> , 2015, 16, 164-170.	1.0	47
125	Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysis. <i>European Journal of Cancer</i> , 2015, 51, 800-807.	1.3	46
126	Treatment of lung large cell neuroendocrine carcinoma. <i>Tumor Biology</i> , 2016, 37, 7047-7057.	0.8	46

#	ARTICLE	IF	CITATIONS
127	Better Together: Targeted Combination Therapies in Breast Cancer. <i>Seminars in Oncology</i> , 2015, 42, 887-895.	0.8	45
128	The Pan-Immune-Inflammation Value in microsatellite instabilityâ€“high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 150, 155-167.	1.3	45
129	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. <i>Oncotarget</i> , 2016, 7, 3947-3965.	0.8	45
130	Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development. <i>European Journal of Cancer</i> , 2008, 44, 494-500.	1.3	44
131	In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. <i>British Journal of Cancer</i> , 2006, 95, 289-297.	2.9	43
132	Participation in Clinical Trials as Viewed by the Patient: Understanding Cultural and Emotional Aspects Which Influence Choice. <i>Oncology</i> , 2008, 74, 177-187.	0.9	42
133	Single-Agent Panitumumab in Frail Elderly Patients With Advanced <i>RAS</i> and <i>BRAF</i> Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. <i>Oncologist</i> , 2015, 20, 1261-1265.	1.9	42
134	Preoperative versus postoperative docetaxelâ€“cisplatinâ€“fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. <i>Annals of Oncology</i> , 2016, 27, 668-673.	0.6	42
135	5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (TaxotereÂ®)â€“cisplatin in advanced gastric carcinoma: a phase Iâ€“II trial. <i>Annals of Oncology</i> , 2004, 15, 759-764.	0.6	41
136	Prognostic Role of Pancreatic Metastases FromÂRenal Cell Carcinoma: Results From an Italian Center. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 484-488.	0.9	41
137	Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 57-73.	2.0	41
138	HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 1768-1771.	0.6	40
139	MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review. <i>Frontiers in Oncology</i> , 2018, 8, 650.	1.3	40
140	Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5â€“fluorouracil: a metaâ€“analysis of published trials. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1228-1237.	1.1	39
141	Synergistic Activity of Oxaliplatin and 5-Fluorouracil in Patients With Metastatic Colorectal Cancer With Progressive Disease While on or After 5-Fluorouracil. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 279-283.	0.6	39
142	First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. <i>Cancer</i> , 2007, 110, 752-758.	2.0	38
143	Capecitabine Initially Concomitant to Radiotherapy Then Perioperatively Administered in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 421-427.	0.4	38
144	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. <i>European Urology Oncology</i> , 2019, 2, 699-707.	2.6	38

#	ARTICLE	IF	CITATIONS
145	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2858.	1.6	38
146	Osteopontin, E-cadherin, and β -catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 412-420.	2.7	37
147	A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. <i>Oncotarget</i> , 2015, 6, 5118-5133.	0.8	37
148	Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 110-124.	2.0	36
149	Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. <i>Cancer Treatment Reviews</i> , 2010, 36, S87-S94.	3.4	36
150	Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders. <i>Cancer Treatment Reviews</i> , 2014, 40, 197-203.	3.4	36
151	Lymphoma Immunotherapy: Current Status. <i>Frontiers in Immunology</i> , 2015, 6, 448.	2.2	36
152	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , 2016, 1, e000127.	2.0	36
153	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , 2016, 14, 125.	1.8	36
154	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , 2020, 12, 1727.	1.7	36
155	Treatment of Carcinoid Syndrome with Recombinant Interferon Alpha-2a. <i>Acta Oncologica</i> , 1993, 32, 235-238.	0.8	35
156	High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible?. <i>Annals of Oncology</i> , 1998, 9, 917-919.	0.6	35
157	Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2001, 12, 1553-1559.	0.6	35
158	A Catalyst for Change: The European Cancer Patient's Bill of Rights. <i>Oncologist</i> , 2014, 19, 217-224.	1.9	35
159	Diagnosis and management of typical and atypical lung carcinoids. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 167-176.	2.0	35
160	Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 50-59.	1.1	35
161	Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. <i>Annals of Oncology</i> , 2002, 13, 895-902.	0.6	34
162	Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. <i>European Journal of Cancer</i> , 2009, 45, 2116-2122.	1.3	34

#	ARTICLE	IF	CITATIONS
163	18F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 818-830.	3.3	34
164	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5319.	1.8	34
165	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, <i>RAS-BRAF</i> wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2015, 137, 1467-1474.	2.3	33
166	The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy. <i>Targeted Oncology</i> , 2021, 16, 529-536.	1.7	33
167	Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6-6.	0.8	33
168	Identification and characterization of a novel <i>SCYL3-NTRK1</i> rearrangement in a colorectal cancer patient. <i>Oncotarget</i> , 2017, 8, 55353-55360.	0.8	33
169	Characterization of the response of human thymocytes and blood lymphocytes to the synergistic mitogenicity of 12-O-tetradecanoylphorbol-13-acetate (TPA) ionomycin. <i>European Journal of Immunology</i> , 1984, 14, 720-724.	1.6	32
170	Phase II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: A regimen with a low subjective toxic burden. <i>Annals of Oncology</i> , 1997, 8, 865-870.	0.6	32
171	Bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 89-106.	2.0	32
172	Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. <i>Acta Oncologica</i> , 2010, 49, 120-122.	0.8	32
173	Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. <i>Annals of Oncology</i> , 2016, 27, 1782-1787.	0.6	32
174	Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer Is Rare. <i>Journal of Clinical Oncology</i> , 2004, 22, 4966-4970.	0.8	31
175	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 347-352.	2.9	31
176	Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1336-1339.	3.3	30
177	Oligometastatic Non-Small Cell Lung Cancer: A Multidisciplinary Approach in the Positron Emission Tomographic Scan Era. <i>Annals of Thoracic Surgery</i> , 2007, 83, 231-234.	0.7	30
178	A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. <i>Annals of Oncology</i> , 2015, 26, 2341-2346.	0.6	30
179	Colon cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 51, 145-170.	2.0	29
180	Is the Standardized Uptake Value of FDG-PET/CT Predictive of Pathological Complete Response in Locally Advanced Rectal Cancer Treated with Capecitabine-Based Neoadjuvant Chemoradiation?. <i>Oncology</i> , 2013, 84, 191-199.	0.9	29

#	ARTICLE	IF	CITATIONS
181	Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. <i>Thrombosis Research</i> , 2016, 140, S55-S59.	0.8	29
182	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. <i>Future Oncology</i> , 2016, 12, 1251-1260.	1.1	29
183	Microenvironment and tumor inflammatory features improve prognostic prediction in gastroenteropancreatic neuroendocrine neoplasms. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 217-226.	1.3	29
184	Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2010, 103, 837-844.	2.9	28
185	“Waiting and the Waiting Room: How Do You Experience Them?” Emotional Implications and Suggestions from Patients with Cancer. <i>Journal of Cancer Education</i> , 2011, 26, 388-394.	0.6	28
186	Vaccines in non-small cell lung cancer: Rationale, combination strategies and update on clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 432-443.	2.0	28
187	Everolimus and Temozolomide Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 137-141.	0.9	28
188	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 315-321.	0.3	28
189	Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study. <i>Clinical Breast Cancer</i> , 2017, 17, 219-231.	1.1	28
190	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. <i>Cancer Treatment Reviews</i> , 2020, 88, 102057.	3.4	28
191	IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in KRAS mutant metastatic colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 16887-16898.	0.8	28
192	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens. <i>Cancer Biology and Therapy</i> , 2013, 14, 1098-1103.	1.5	27
193	Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015, 7, 152-161.	0.9	27
194	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , 2017, 71, 43-50.	1.3	27
195	Exploiting Fasting-mimicking Diet and Metformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. <i>Clinical Lung Cancer</i> , 2019, 20, e413-e417.	1.1	27
196	Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. <i>Lung Cancer</i> , 2018, 115, 135-142.	0.9	27
197	Role of MGMT as biomarker in colorectal cancer. <i>World Journal of Clinical Cases</i> , 2014, 2, 835.	0.3	27
198	Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2000, 11, 821-827.	0.6	26

#	ARTICLE	IF	CITATIONS
199	Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1560-1569.	0.5	26
200	Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 479-482.	0.6	26
201	A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2146-2154.	3.2	26
202	The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. <i>Seminars in Cancer Biology</i> , 2020, 60, 344-350.	4.3	26
203	Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. <i>Breast Cancer Research</i> , 2020, 22, 33.	2.2	26
204	Immunotherapy-based combinations: an update. <i>Current Opinion in Oncology</i> , 2018, 30, 345-351.	1.1	25
205	Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?. <i>Journal of Clinical Medicine</i> , 2020, 9, 930.	1.0	25
206	Phase II Study of the Etoposide, Leucovorin and Fluorouracil Combination for Patients with Advanced Gastric Cancer Unsuitable for Aggressive Chemotherapy. <i>Oncology</i> , 1995, 52, 41-44.	0.9	24
207	Fasting-mimicking diet plus chemotherapy in breast cancer treatment. <i>Nature Communications</i> , 2020, 11, 4274.	5.8	24
208	Practical Considerations in the Treatment of Hepatocellular Carcinoma. <i>Drugs</i> , 1998, 55, 367-382.	4.9	23
209	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , 2016, 11, 337-343.	1.7	23
210	miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	23
211	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021, 152, 165-173.	0.9	23
212	Lessons from the Iressa™ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. <i>British Journal of Cancer</i> , 2003, 89, S19-S23.	2.9	22
213	Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. <i>Pharmacogenomics Journal</i> , 2010, 10, 180-190.	0.9	22
214	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , 2015, 32, 182.	1.2	22
215	Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 425-437.	1.1	22
216	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. <i>Cancer Letters</i> , 2021, 511, 77-87.	3.2	22

#	ARTICLE	IF	CITATIONS
217	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1017-1024.	3.2	22
218	Preoperative chemotherapy is essential for conservative surgery of Askin tumors. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 125, 428-429.	0.4	21
219	Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. <i>Annals of Oncology</i> , 2015, 26, 838-847.	0.6	21
220	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016, 34, 236-242.	1.2	21
221	Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 24-28.	2.0	21
222	Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. <i>International Journal of Cancer</i> , 2019, 145, 576-585.	2.3	21
223	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. <i>Haematologica</i> , 2020, 105, 1704-1711.	1.7	21
224	ecancermedalscience. <i>Ecancermedalscience</i> , 2011, 5, 201.	0.6	20
225	Salvage Treatment After Interferon α -2a in Advanced Neuroendocrine Tumors. <i>Acta Oncologica</i> , 1993, 32, 245-250.	0.8	20
226	Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). <i>Annals of Oncology</i> , 1999, 10, 993-996.	0.6	20
227	Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. <i>Annals of Oncology</i> , 2002, 13, 161-166.	0.6	20
228	Challenging Lung Carcinoma with Coexistent ^{63}Ni /p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1500-1502.	0.5	20
229	MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S393-S394.	0.5	20
230	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019, 144, 1704-1712.	2.3	20
231	Expression of the T1 (CD5, p67) surface antigen in B-CLL and B-NHL and its correlation with other B-cell differentiation markers. <i>Hematological Oncology</i> , 1986, 4, 237-248.	0.8	19
232	Cancer of pancreas. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 147-155.	2.0	19
233	Bax Expression Is Predictive of Favorable Clinical Outcome in Chemonaive Advanced Gastric Cancer Patients Treated with Capecitabine, Oxaliplatin, and Irinotecan Regimen. <i>Translational Oncology</i> , 2012, 5, 155-159.	1.7	19
234	Immunotherapy advances in uro-genital malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 52-64.	2.0	19

#	ARTICLE	IF	CITATIONS
235	Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. <i>European Journal of Cancer</i> , 2022, 172, 300-310.	1.3	19
236	Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. <i>Lung Cancer</i> , 2001, 31, 267-270.	0.9	18
237	Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. <i>Annals of Oncology</i> , 2006, 17, 1174-1175.	0.6	18
238	Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey. <i>Tumori</i> , 2009, 95, 647-651.	0.6	18
239	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. <i>British Journal of Cancer</i> , 2012, 107, 1227-1232.	2.9	18
240	Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. <i>PLoS ONE</i> , 2014, 9, e92147.	1.1	18
241	Body Mass Index and Clinical Benefit of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer. <i>Tumori</i> , 2016, 102, e11-e14.	0.6	18
242	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	1.6	18
243	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. <i>Cancers</i> , 2019, 11, 223.	1.7	18
244	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e002501.		18
245	Three-Times-Daily Radiotherapy with Induction Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 363-371.	1.0	17
246	Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung. <i>Lung Cancer</i> , 2005, 48, 233-240.	0.9	17
247	Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. <i>Prostate</i> , 2007, 67, 603-604.	1.2	17
248	Experience with sorafenib in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2012, 4, 303-313.	0.9	17
249	Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. <i>Patient Preference and Adherence</i> , 2013, 7, 391.	0.8	17
250	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	2.9	17
251	A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer. <i>International Journal of Cancer</i> , 2020, 146, 3495-3503.	2.3	17
252	Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 82, 101935.	3.4	17

#	ARTICLE	IF	CITATIONS
253	Thrombin generation predicts early recurrence in breast cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2220-2231.	1.9	17
254	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. <i>Clinical Lung Cancer</i> , 2021, 22, 161-169.	1.1	17
255	Drug-Induced Prolongation of the QT Interval. <i>New England Journal of Medicine</i> , 2004, 350, 2618-2621.	13.9	16
256	Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 131-134.	0.5	16
257	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. <i>British Journal of Cancer</i> , 2014, 110, 26-33.	2.9	16
258	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. <i>Tumor Biology</i> , 2016, 37, 12991-13003.	0.8	16
259	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. <i>Pharmacogenomics Journal</i> , 2019, 19, 465-472.	0.9	16
260	Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. <i>Clinical Breast Cancer</i> , 2019, 19, e306-e318.	1.1	16
261	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	1.0	16
262	Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. <i>Tumori</i> , 2014, 100, e286-9.	0.6	16
263	Gastrointestinal Stromal Tumors: Should They Be Treated with the Same Systemic Chemotherapy as Other Soft Tissue Sarcomas?. <i>Oncology</i> , 2003, 64, 186-188.	0.9	15
264	Adjuvant Therapy for Very Young Women with Breast Cancer: Response According to Biologic and Endocrine Features. <i>Clinical Breast Cancer</i> , 2004, 5, 125-130.	1.1	15
265	Factor V Leiden Mutation in Patients with Breast Cancer with a Central Venous Catheter: Risk of Deep Vein Thrombosis. <i>Supportive Cancer Therapy</i> , 2006, 3, 98-102.	0.3	15
266	“Burned out” phenomenon of the testis in retroperitoneal seminoma. <i>Acta Oncologica</i> , 2006, 45, 335-336.	0.8	15
267	Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable or Metastatic Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 203-209.e1.	0.9	15
268	Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 272-281.	2.0	15
269	Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2167-2172.	2.0	15
270	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Targeted Oncology</i> , 2018, 13, 795-800.	1.7	15

#	ARTICLE	IF	CITATIONS
271	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. <i>Oncotarget</i> , 2016, 7, 44841-44847.	0.8	15
272	Hyperfractionated Radiotherapy in Locally Advanced Nasopharyngeal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 425-433.	1.0	14
273	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 160-182.	2.0	14
274	Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach. <i>Journal of Thoracic Oncology</i> , 2011, 6, 768-773.	0.5	14
275	Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens. <i>Cancers</i> , 2014, 6, 1753-1768.	1.7	14
276	BRAF in metastatic colorectal cancer: the future starts now. <i>Pharmacogenomics</i> , 2015, 16, 2069-2081.	0.6	14
277	Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 651-662.	1.4	14
278	Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e735-e742.	0.9	14
279	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019, 4, e000489.	2.0	14
280	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , 2020, 25, 780-786.	1.9	14
281	START: A European state-of-the-art on-line instrument for clinical oncologists. <i>Annals of Oncology</i> , 1999, 10, 769-774.	0.6	13
282	Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 301-306.	1.1	13
283	Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase. <i>International Journal of Molecular Sciences</i> , 2015, 16, 8884-8895.	1.8	13
284	Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 323-330.	1.4	13
285	Updated overall efficacy and safety of selipercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9065-9065.	0.8	13
286	COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study. <i>ESMO Open</i> , 2020, 5, e000883.	2.0	13
287	Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. <i>European Journal of Cancer</i> , 1994, 30, 596-600.	1.3	12
288	Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?. <i>Annals of Oncology</i> , 2000, 11, 117-118.	0.6	12

#	ARTICLE	IF	CITATIONS
289	Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced colorectal cancer treated with gefitinib?. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 139-148.	1.1	12
290	A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer. <i>Acta Oncol</i> 2010, 49, 480-484.	0.8	12
291	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 332.e19-332.e24.	0.8	12
292	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017, 16, e191-e198.	1.0	12
293	Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. <i>Pharmacogenomics</i> , 2018, 19, 1047-1068.	0.6	12
294	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , 2019, 18, e179-e190.	1.0	12
295	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , 2019, 132, 17-23.	0.9	12
296	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 31-40.	1.3	12
297	EGFR Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1561-1569.	3.0	12
298	Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. <i>Anti-Cancer Drugs</i> , 2007, 18, 949-954.	0.7	12
299	5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 16437-16450.	0.8	12
300	DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. <i>Cells</i> , 2020, 9, 1260.	1.8	12
301	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017, 49, 834-845.	1.3	12
302	Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group. <i>British Journal of Cancer</i> , 2003, 88, 645-647.	2.9	11
303	QTc prolongation assessment in anticancer drug development: Clinical and methodological issues. <i>Ecancermedalscience</i> , 2009, 3, 130.	0.6	11
304	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 99-106.	2.0	11
305	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017, 6, 1493-1499.	1.3	11
306	Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	11

#	ARTICLE	IF	CITATIONS
307	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020, 135, 230-239.	1.3	11
308	Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients. , 2021, 9, e001167.		11
309	Pharmacogenetics and Proteomics of Anticancer Drugs in Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, S115-S122.	0.6	10
310	<i>TP53</i> Mutations in Advanced Colorectal Cancer: The Dark Side of the Moon. <i>Oncology</i> , 2014, 86, 289-294.	0.9	10
311	HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature. <i>Breast Care</i> , 2016, 11, 424-426.	0.8	10
312	Trastuzumab Cardiac Toxicity: A Problem we Put our Heart Into. <i>Tumori</i> , 2016, 102, 1-5.	0.6	10
313	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. <i>Pharmacogenomics Journal</i> , 2017, 17, 331-336.	0.9	10
314	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017, 2, e000241.	2.0	10
315	Uncommon Somatic Mutations in Metastatic NUT Midline Carcinoma. <i>Tumori</i> , 2017, 103, S5-S8.	0.6	10
316	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020, 135, 78-88.	1.3	10
317	Ifosfamide in the elderly: clinical considerations for a better drug management. <i>Critical Reviews in Oncology/Hematology</i> , 2000, 33, 129-135.	2.0	9
318	Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. <i>Annals of Oncology</i> , 2009, 20, 498-502.	0.6	9
319	Safety, Tolerability and Biological Effects of Long-Term Metronomic Administration of Non-Cytotoxic Anti-Angiogenic Agents. <i>Oncology</i> , 2009, 77, 358-365.	0.9	9
320	Phase Ib of Sorafenib in Combination With Everolimus in Patients With Advanced Solid Tumors, Selected on the Basis of Molecular Targets. <i>Oncologist</i> , 2014, 19, 344-345.	1.9	9
321	Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. <i>Future Oncology</i> , 2014, 10, 1361-1372.	1.1	9
322	Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. <i>Future Oncology</i> , 2015, 11, 1947-1959.	1.1	9
323	Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 171-177.e1.	0.9	9
324	Treatment of elderly patients with metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 323-334.	1.1	9

#	ARTICLE	IF	CITATIONS
325	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , 2019, 107, 164-174.	1.3	9
326	Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections. <i>HemaSphere</i> , 2020, 4, e408.	1.2	9
327	Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. <i>TH Open</i> , 2021, 05, e56-e65.	0.7	9
328	A phase 2 prospective trial of cabozantinib as first-line treatment for metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2) clinical trial information NCT03354884. <i>Journal of Clinical Oncology</i> , 2021, 39, 4571-4571.	0.8	9
329	Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA). <i>Journal of Clinical Oncology</i> , 2012, 30, 388-388.	0.8	9
330	Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study. <i>Cancers</i> , 2022, 14, 69.	1.7	9
331	Induction chemotherapy followed by simultaneous hyperfractionated radiochemotherapy in advanced head and neck cancer. <i>Strahlentherapie Und Onkologie</i> , 1998, 174, 457-461.	1.0	8
332	Rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 51, 121-143.	2.0	8
333	Does Immunohistochemistry Affect Response to Therapy and Survival of Inoperable Non-Small Cell Lung Carcinoma Patients? A Survey of 145 Stage III-IV Consecutive Cases. <i>International Journal of Surgical Pathology</i> , 2014, 22, 136-148.	0.4	8
334	Safety profile and treatment response of everolimus in different solid tumors: an observational study. <i>Future Oncology</i> , 2014, 10, 1611-1617.	1.1	8
335	Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?. <i>Tumori</i> , 2016, 102, 18-30.	0.6	8
336	The underestimated role of somatostatin analogs in the NETTER-1 trial. <i>Future Oncology</i> , 2017, 13, 1287-1289.	1.1	8
337	Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. <i>Endocrine</i> , 2017, 57, 512-517.	1.1	8
338	Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 902.	1.3	8
339	Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 261-268.	1.3	8
340	Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. <i>Supportive Care in Cancer</i> , 2005, 13, 194-195.	1.0	7
341	Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma. <i>Acta Oncologica</i> , 2006, 45, 627-629.	0.8	7
342	Miliary Hepatic Metastases from Neuroendocrine Carcinoma. <i>Digestive Surgery</i> , 2008, 25, 330-330.	0.6	7

#	ARTICLE	IF	CITATIONS
343	Role of BAX for outcome prediction in gastrointestinal malignancies. <i>Medical Oncology</i> , 2013, 30, 610.	1.2	7
344	Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials. <i>Future Oncology</i> , 2013, 9, 1451-1458.	1.1	7
345	Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity. <i>Future Oncology</i> , 2013, 9, 1599-1607.	1.1	7
346	First line treatment of metastatic renal cell carcinoma. <i>Cancer Biology and Therapy</i> , 2014, 15, 19-21.	1.5	7
347	Improved health perception after genetic counselling for women at high risk of breast and/or ovarian cancer: construction of new questionnairesâ€”an Italian exploratory study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 633-648.	1.2	7
348	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. <i>Future Oncology</i> , 2019, 15, 2743-2757.	1.1	7
349	The role of metastasectomy in advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 603-611.	1.1	7
350	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019, 18, 116-124.	1.0	7
351	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	1.0	7
352	Phase II Trial of Vinorelbine, Cisplatin and Continuous Infusion of 5-Fluorouracil Followed by Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer. <i>Oncology</i> , 2002, 63, 115-123.	0.9	6
353	Imatinib administration in two patients with liver metastases from GIST and severe jaundice. <i>British Journal of Cancer</i> , 2003, 89, 1403-1404.	2.9	6
354	Reply to the article â€œMetronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicityâ€”by V. R. Rozados et al. (<i>Ann Oncol</i> 2004; 15: 1543â€“1550): â€” and in humans?. <i>Annals of Oncology</i> , 2005, 16, 673.	0.6	6
355	Erlotinib Combined with Cyclosporine in a Liver-Transplant Recipient with Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 138-139.	0.5	6
356	Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum. <i>Cancers</i> , 2012, 4, 808-820.	1.7	6
357	Biological insights into BRAF^{V600} mutations in melanoma patient. <i>OncolImmunology</i> , 2013, 2, e25594.	2.1	6
358	Combined Therapy with Dabrafenib and Trametinib in BRAF-Mutated Metastatic Melanoma in a Real-Life Setting: The INT Milan Experience. <i>Tumori</i> , 2016, 102, 501-507.	0.6	6
359	Immunohistochemical Detection of HER1/HER2 Can Be Considered a Predictive Marker of Gefitinib Activity in Non-Small-Cell Lung Cancer?. <i>Journal of Clinical Oncology</i> , 2005, 23, 921-922.	0.8	5
360	A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. <i>Lung Cancer</i> , 2006, 54, 359-364.	0.9	5

#	ARTICLE	IF	CITATIONS
361	Health-Related Quality of Life in Patients with Hormone Refractory Prostate Cancer Receiving Gefitinib. <i>Urologia Internationalis</i> , 2009, 82, 196-202.	0.6	5
362	Targeted treatments in advanced renal cell carcinoma: focus on axitinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 107.	0.4	5
363	Improved quality of life is the way to longer life. <i>Lancet Oncology</i> , The, 2016, 17, 862-863.	5.1	5
364	Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio. <i>Journal of Clinical Oncology</i> , 2016, 34, 1017-1018.	0.8	5
365	Complete remission in metastatic breast cancer: expecting the unexpectedâ€”results of a cross-sectional study. <i>Breast Cancer</i> , 2017, 24, 635-641.	1.3	5
366	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. <i>Future Oncology</i> , 2017, 13, 1677-1683.	1.1	5
367	ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?. <i>Thrombosis Research</i> , 2020, 194, 176-177.	0.8	5
368	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103299.	2.0	5
369	Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair deficient (dMMR) GI cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 218-218.	0.8	5
370	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 115-121.	1.1	5
371	Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103532.	2.0	5
372	Adjuvant Chemotherapy for Cancer of Gastrointestinal Tract: A Critical Review. <i>Tumori</i> , 1992, 78, 228-234.	0.6	4
373	Pharmacokinetics of Oral Doxifluridine in Patients with Colorectal Cancer. <i>Tumori</i> , 1999, 85, 47-50.	0.6	4
374	Is there a Real Advantage in Utilizing Central Venous Ports in Oncology Surgery? An Analysis of the Cost-Effectiveness Ratio. <i>Tumori</i> , 2001, 87, 74-75.	0.6	4
375	Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and EpiDoxorubicin in a Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1345-1346.	3.0	4
376	Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials. <i>Trials</i> , 2008, 9, 46.	0.7	4
377	Optimizing Clinical Care in Patients with Advanced Soft Tissue Sarcoma: A Phase II Study of a New Schedule of High-Dose Continuous Infusion Ifosfamide and Doxorubicin Combination. <i>Chemotherapy</i> , 2011, 57, 217-224.	0.8	4
378	Targeted Therapies and Survival: What We Can Learn from Studies in Advanced Renal Cell Carcinoma. <i>Oncology</i> , 2013, 84, 39-42.	0.9	4

#	ARTICLE	IF	CITATIONS
379	Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity. <i>Personalized Medicine</i> , 2014, 11, 259-262.	0.8	4
380	Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients. <i>Oncology</i> , 2015, 88, 133-138.	0.9	4
381	Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities A Case Report with a 6-Year Follow-Up. <i>Case Reports in Oncology</i> , 2016, 9, 432-439.	0.3	4
382	Update on medical treatment of small intestinal neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 969-976.	1.1	4
383	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e81-e90.	0.9	4
384	Should clinicians always administer dexamethasone beyond 24h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies. <i>Supportive Care in Cancer</i> , 2016, 24, 1025-1034.	1.0	4
385	Combination therapies for patients with metastatic renal cell carcinoma. <i>Lancet Oncology</i> , The, 2018, 19, 281-283.	5.1	4
386	Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma. <i>Tumori</i> , 2019, 105, 465-473.	0.6	4
387	Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma. <i>Tumori</i> , 2021, 107, 542-549.	0.6	4
388	SMO mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2020, 9, 1940-1951.	1.3	4
389	Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities. <i>Tumori</i> , 2013, 99, e148-51.	0.6	4
390	Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. <i>Tumori</i> , 2012, 98, 279-86.	0.6	4
391	Central venous catheters-related-thrombosis and risk factors in oncological patients: A retrospective evaluation of recent risk scores. <i>Tumori</i> , 2023, 109, 363-369.	0.6	4
392	Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 461-462.	3.0	3
393	Prophylaxis for Venous Thromboembolism in Cancer Patients With a Central Vein Catheter: New Tones for an Old Song. <i>Journal of Clinical Oncology</i> , 2005, 23, 7243-7244.	0.8	3
394	Tackling Off-Label Use of Anticancer Drugs. <i>Journal of Clinical Oncology</i> , 2012, 30, 2800-2800.	0.8	3
395	Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>Eur Urol</i> 2012;61:826-33. <i>European Urology</i> , 2012, 62, e5-e6.	0.9	3
396	To Target or Not to Target, That Is the Question. <i>Journal of Clinical Oncology</i> , 2013, 31, 1254-1254.	0.8	3

#	ARTICLE	IF	CITATIONS
397	Is a Dexamethasone-Sparing Strategy Capable of Preventing Acute and Delayed Emesis Caused by Combined Doxorubicin and Paclitaxel for Breast Cancer Analysis of a Phase II Trial. <i>Oncology</i> , 2013, 84, 371-377.	0.9	3
398	Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron?. <i>Journal of Clinical Oncology</i> , 2014, 32, 2185-2186.	0.8	3
399	Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR Mutations?. <i>Journal of Clinical Oncology</i> , 2014, 32, 859-863.	0.8	3
400	Prognosis of women with early breast cancer and PIK3CA mutations. <i>Breast</i> , 2015, 24, 283-284.	0.9	3
401	Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, E403-E407.	0.6	3
402	Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. <i>Future Oncology</i> , 2019, 15, 3015-3024.	1.1	3
403	A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors. <i>Cancers</i> , 2020, 12, 1425.	1.7	3
404	Integrated transcriptional and phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. <i>Clinical and Translational Medicine</i> , 2021, 11, e434.	1.7	3
405	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with <i>RAS</i> Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. <i>Oncologist</i> , 2022, 27, e29-e36.	1.9	3
406	Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. <i>Future Oncology</i> , 2022, 18, 2593-2604.	1.1	3
407	Activity and Tolerability of Courses of Intra-Arterial Chemotherapy Followed by Chemoembolization in Unresectable Hepatocellular Carcinoma. <i>Tumori</i> , 1998, 84, 673-676.	0.6	2
408	Very low acute toxicity of three fractions per day accelerated radiotherapy given after induction chemotherapy and surgery in stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2000, 30, 149-150.	0.9	2
409	Target-Treatment and Patients' Selection: Can We Still Neglect the Timing of Tissue Collection?. <i>Journal of Clinical Oncology</i> , 2005, 23, 6274-6275.	0.8	2
410	Reply to Letter to the Editor: "Toxic epidermal necrolysis in patients with malignancies", by G. Gravante, G. Esposito, M. Marianetti, D. Delogu, G. Sconocchia & A. Montone (doi:10.1093/annonc/mdl089). <i>Annals of Oncology</i> , 2006, 17, 1601-1602.	0.6	2
411	A 15-min premedication for 1-h paclitaxel infusion: Optimizing patients' care. <i>Lung Cancer</i> , 2007, 58, 300-301.	0.9	2
412	Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration. <i>Annals of Oncology</i> , 2009, 20, 1747-1748.	0.6	2
413	Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. <i>Clinical and Translational Oncology</i> , 2013, 15, 582-586.	1.2	2
414	Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?. <i>Annals of Oncology</i> , 2013, 24, 1415-1416.	0.6	2

#	ARTICLE	IF	CITATIONS
415	Butterfly and Renal Cell Cancer: Out of Chaos Comes Order. <i>Journal of Clinical Oncology</i> , 2014, 32, 3083-3083.	0.8	2
416	Study design and clinical evidence in mRCC. <i>Cancer Biology and Therapy</i> , 2014, 15, 486-488.	1.5	2
417	Clinical Outcome of HER2-positive Breast Cancer Patients after Failure on Adjuvant Trastuzumab: The Potential of the Time to Relapse. <i>Clinical Oncology</i> , 2014, 26, 174.	0.6	2
418	Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. <i>Clinical Interventions in Aging</i> , 2015, 10, 127.	1.3	2
419	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. <i>Therapeutic Advances in Urology</i> , 2015, 7, 59-68.	0.9	2
420	Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. <i>Clinical and Translational Oncology</i> , 2015, 17, 530-538.	1.2	2
421	Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 451-461.	1.4	2
422	New perspectives in advanced genitourinary malignancies. <i>Tumori</i> , 2012, 98, 267-9.	0.6	2
423	Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 17588359211006960.	1.4	2
424	<sc>MGMT</sc> inactivation as a new biomarker in patients with advanced biliary tract cancers. <i>Molecular Oncology</i> , 2022, 16, 2733-2746.	2.1	2
425	LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIa <i>RET</i> fusion-positive NSCLC. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8594-TPS8594.	0.8	2
426	Preoperative Chemotherapy in Nonâ€“Small-Cell Lung Cancer: Nothing New in N2 Disease. <i>Journal of Clinical Oncology</i> , 2002, 20, 2603-2604.	0.8	1
427	CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. <i>Annals of Oncology</i> , 2004, 15, 1850.	0.6	1
428	Adjuvant Chemotherapy in New Stage II pN0 Non-small Cell Lung Cancer: A New Issue for a Case-By-Case Decision Making Process. <i>Journal of Thoracic Oncology</i> , 2010, 5, 754.	0.5	1
429	Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancerâ€“subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. <i>Annals of Oncology</i> , 2012, 23, 2771-2772.	0.6	1
430	Features and Prognostic Factors of Large Node-Negative Nonâ€“Small-Cell Lung Cancers Shifted to Stage II. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1124-1130.	0.5	1
431	Adjuvant treatment of colorectal cancer in the elderly: Where do we come from and where are we going?. <i>Journal of Solid Tumors</i> , 2012, 2, .	0.1	1
432	FOLFIRI with cetuximab or bevacizumab: FIRE-3. <i>Lancet Oncology</i> , The, 2014, 15, e581.	5.1	1

#	ARTICLE	IF	CITATIONS
433	In Reply. <i>Oncologist</i> , 2015, 20, e5-e5.	1.9	1
434	Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2015, 30, 429-430.	1.0	1
435	Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer. <i>Breast</i> , 2016, 27, 187-188.	0.9	1
436	Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	1
437	Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4167-TPS4167.	0.8	1
438	Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion+ non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9032-9032.	0.8	1
439	A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 14647-14647.	0.8	1
440	Pharmacokinetic (PK) and pharmacodynamic (PD) analysis from a phase I study of PF-03446962, a fully human mab against ALK1, a TGF-beta receptor involved in tumor angiogenesis.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13606-e13606.	0.8	1
441	Update on Therapeutic Strategy in Lung Carcinoids. <i>Journal of Cancer Therapy</i> , 2013, 04, 1466-1471.	0.1	1
442	Trends in exposure to multiple lines of treatment and survival of patients with metastatic renal cell carcinoma: A real-world analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16064-e16064.	0.8	1
443	Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model. <i>Frontiers in Oncology</i> , 2022, 12, 857515.	1.3	1
444	Erratum to "A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients" [Lung cancer 54 (2006) 359-364]. <i>Lung Cancer</i> , 2007, 58, 431.	0.9	0
445	Right pelvic mass in a patient with a radically resected carcinoid of the appendix. <i>Gut</i> , 2009, 58, 1200-1200.	6.1	0
446	"Systemic Strategy at the Patient's Service" A Congress Report on Supportive Care in Oncology. <i>Tumori</i> , 2017, 103, P1-P8.	0.6	0
447	A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5052-5052.	0.8	0
448	Pharmacogenetics in Oncology. , 2006, , 129-153.		0
449	Pharmacokinetic modeling and simulation (PK M&S) supported dose escalation of PF-03446962, a monoclonal antibody (mAb) against activin receptor like kinase 1, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2595-2595.	0.8	0
450	Rationale and Protocol of SOAP: A Phase II Study to Evaluate the Efficacy of Sorafenib as Second-Line Treatment after Pazopanib in Patients with Advanced Renal Cell Carcinoma. <i>Tumori</i> , 2014, 100, e282-e285.	0.6	0

#	ARTICLE	IF	CITATIONS
451	Multidisciplinary Approach of Prostate Cancer Patients. , 2017, , 281-293.		0
452	Whole-exome sequencing in radically resected gastric cancer (GC): Analysis of patients (pts) with poor prognostic factors from the Italian Trial of Adjuvant Chemotherapy Adenocarcinoma (ITACA-S) trial.. Journal of Clinical Oncology, 2017, 35, 64-64.	0.8	0
453	Safety and antitumor activity of weekly carboplatin plus paclitaxel in metastatic breast cancer: A ten years, single-institution, retrospective analysis.. Journal of Clinical Oncology, 2017, 35, e12556-e12556.	0.8	0
454	mutations confer poor prognosis in malignant pleural mesothelioma. Translational Lung Cancer Research, 2020, 9, 1940-1951.	1.3	0
455	Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma. Tumori, 2014, 100, e282-5.	0.6	0
456	PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers.. Journal of Clinical Oncology, 2022, 40, 9033-9033.	0.8	0
457	PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: A multiomics approach.. Journal of Clinical Oncology, 2022, 40, 9051-9051.	0.8	0
458	Genomic determinants and clinical relevance of cancer-associated thrombosis in biliary tract cancers.. Journal of Clinical Oncology, 2022, 40, e16179-e16179.	0.8	0